| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 460 6 |
| Ultima descărcare din IBN: 2021-11-24 14:23 |
| Căutarea după subiecte similare conform CZU |
| 616.98:578.834.1-078 (1) |
| Инфекционные заболевания. Инфекционные лихорадки (587) |
| Вирусология (446) |
 SM ISO690:2012SPÎNU, Constantin, CEBOTARI, Svetlana, SAJIN, Octavian, SPÎNU, Igor, DONOS, Ala, VOLNEANSCHI, Ana, GOSTEV, Igor, DOPIRA, Iurie. Evaluarea prezenței anticorpilor anti SARS-CoV- 2 la donatorii de plasmă convalescentă cu scopul de a argumenta utilizarea lor în tratamentul COVID-19. In: One Health and Risk Management, 2021, nr. 2(2), pp. 58-64. ISSN 2587-3458. DOI: https://doi.org/10.38045/ohrm.2021.2.08 |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
 One Health and Risk Management |
||
| Numărul 2(2) / 2021 / ISSN 2587-3458 /ISSNe 2587-3466 | ||
|
||
| DOI:https://doi.org/10.38045/ohrm.2021.2.08 | ||
| CZU: 616.98:578.834.1-078 | ||
| Pag. 58-64 | ||
 Descarcă PDF |
||
| Rezumat | ||
Introduction. Currently, COVID-19 treatment includes several options, including the use of convalescent plasma. Therefore, the presence of anti-SARS-CoV-2 in blood donors after the clinical recovery of COVID-19, depending on their place of residence, age and the clinical manifestation of the disease is of scientific-practical interest. Material and methods. A total of 119 donors among patients were examined, namely males aged 18-60 years, having a past history of COVID-19 disease, being confirmed by PCR and treated, showing a negative PCR-based test result, which was performed at least 14 days after clinical recovery. The presence/absence of anti-SARS-CoV-2 was assessed by enzyme-linked immunosorbent assay. Results. The obtained data showed that 87.4% of plasma donors responded to COVID-19 infection by anti-SARS-CoV-2 IgG expression, being predominantly found in the 26-35 age group. Most donors experienced mild and medium clinical forms. It is important to note that all severe clinical manifestations of the infection were followed by formation of antiSARS-CoV-2 IgG. Urban living environment was predominantly found in convalescent donors (75.0%), which indicates that they are better informed by medical institutions. Conclusions. The study shows that male blood donors aged 18-60 years, subsequently cured and being positive to anti-SARS-CoV-2 IgG can serve as a source of fresh plasma used for the treatment of COVID-19 patients. |
||
| Cuvinte-cheie COVID-19 treatment, plasma donors, anti SARSCoV2, IgG class antibodies, tratamentul COVID-19, plasma donatorilor, anti SARS-CoV-2, anticorpi IgG |
||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-126804</cfResPublId> <cfResPublDate>2021-04-07</cfResPublDate> <cfVol>2</cfVol> <cfIssue>2</cfIssue> <cfStartPage>58</cfStartPage> <cfISSN>2587-3458</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/126804</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Evaluarea prezenței anticorpilor anti SARS-CoV- 2 la donatorii de plasmă convalescentă cu scopul de a argumenta utilizarea lor în tratamentul COVID-19</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>COVID-19 treatment; plasma donors; anti SARSCoV2; IgG class antibodies; tratamentul COVID-19; plasma donatorilor; anti SARS-CoV-2; anticorpi IgG</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Introduction. Currently, COVID-19 treatment includes several options, including the use of convalescent plasma. Therefore, the presence of anti-SARS-CoV-2 in blood donors after the clinical recovery of COVID-19, depending on their place of residence, age and the clinical manifestation of the disease is of scientific-practical interest. Material and methods. A total of 119 donors among patients were examined, namely males aged 18-60 years, having a past history of COVID-19 disease, being confirmed by PCR and treated, showing a negative PCR-based test result, which was performed at least 14 days after clinical recovery. The presence/absence of anti-SARS-CoV-2 was assessed by enzyme-linked immunosorbent assay. Results. The obtained data showed that 87.4% of plasma donors responded to COVID-19 infection by anti-SARS-CoV-2 IgG expression, being predominantly found in the 26-35 age group. Most donors experienced mild and medium clinical forms. It is important to note that all severe clinical manifestations of the infection were followed by formation of antiSARS-CoV-2 IgG. Urban living environment was predominantly found in convalescent donors (75.0%), which indicates that they are better informed by medical institutions. Conclusions. The study shows that male blood donors aged 18-60 years, subsequently cured and being positive to anti-SARS-CoV-2 IgG can serve as a source of fresh plasma used for the treatment of COVID-19 patients.</p></cfAbstr> <cfAbstr cfLangCode='RO' cfTrans='o'><p>Introducere. Tratamentul COVID-19 include mai multe opțiuni, inclusiv utilizarea plasmei convalescente. Astfel, prezintă un interes științifico-practic existența anticorpilor anti SARS-CoV-2 la donatorii de sânge după recuperarea clinică de COVID-19, în funcție de mediul de trai, de vârstă și de forma de manifestare clinică a bolii. Material și metode. Au fost examinați 119 donatori din rândul pacienților, persoane de sex masculin, cu vârsta de 18-60 ani, cu istoric de boală COVID-19, caz confirmat prin PCR, vindecați, cu rezultat negativ pentru COVID-19, confirmat de testul PCR, la cel puțin 14 zile de la recuperarea clinică. Prezența/absența anti SARS-CoV-2 a fost apreciată prin analiza imunoenzimatică. Rezultate. Datele obținute relevă că 87,4% dintre donatorii de plasmă au răspuns la infecția COVID-19 prin expresia anti SARS-CoV-2 IgG, cu predominare în grupul de vârstă de 26-35 ani. Majoritatea donatorilor au făcut forma clinică ușoară și medie. Este important de menționat că toate formele clinice grave de manifestare a infecției au fost însoțite de producerea de anti SARS-CoV-2 IgG. Donatorii sunt preponderent din mediul urban (75%), fapt ce indică că aceștia sunt mai bine informați de instituțiile medicale. Concluzii. Donatorii de sânge de genul masculin, cu vârsta de 18-60 ani, au avut o imunogeneză activă în urma infectării cu SARS-CoV-2, manifestând un nivel înalt de pozitivitate la anticorpii infecției date.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11789</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-54597</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-26482</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-13425</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11057</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-13402</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-39703</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-87552</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> </cfPers_ResPubl> <cfFedId> <cfFedIdId>ibn-doi-126804</cfFedIdId> <cfFedId>10.38045/ohrm.2021.2.08</cfFedId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> <cfFedId_Class> <cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId> <cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId> </cfFedId_Class> <cfFedId_Srv> <cfSrvId>5123451</cfSrvId> <cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId> </cfFedId_Srv> </cfFedId> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11789</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11789-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> <cfFamilyNames>Spînu</cfFamilyNames> <cfFirstNames>Constantin</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-54597</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-54597-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> <cfFamilyNames>Cebotari</cfFamilyNames> <cfFirstNames>Svetlana</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-26482</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-26482-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> <cfFamilyNames>Sajin</cfFamilyNames> <cfFirstNames>Octavian</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-13425</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-13425-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> <cfFamilyNames>Spînu</cfFamilyNames> <cfFirstNames>Igor</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11057</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11057-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> <cfFamilyNames>Донос</cfFamilyNames> <cfFirstNames>Алла</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-13402</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-13402-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> <cfFamilyNames>Volneanschi</cfFamilyNames> <cfFirstNames>Ana</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-39703</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-39703-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> <cfFamilyNames>Гостев</cfFamilyNames> <cfFirstNames>Игорь</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-87552</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-87552-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2021-04-07T24:00:00</cfStartDate> <cfFamilyNames>Dopira</cfFamilyNames> <cfFirstNames>Iurie</cfFirstNames> </cfPersName_Pers> </cfPers> <cfSrv> <cfSrvId>5123451</cfSrvId> <cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName> <cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr> <cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw> </cfSrv> </CERIF>
|
|
|
